Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC
On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC by year-end 2025
Strong financial position with operating runway anticipated into 2028
CAMBRIDGE, Mass., Oct. 30, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating
For further information: Investor Contact: Chelcie Lister, Nuvalent, Inc., clister@nuvalent.com; Media Contact: Josie Butler, 1AB, josie@labmedia.com
